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The International Agency for Research on Cancer (IARC)
Monographs on the carcinogenic risk to humans concluded that
combined oral oestrogen–progestogen contraceptives are carcino-
genic to humans (IARC, 2007). This evaluation was made on the
basis of increased risks for cancer of the breast (among current
and recent users only), cervix and liver (in populations that are at
low risk for hepatitis B viral infection). There is also convincing
evidence in humans that these agents confer a protective effect
against cancer of the endometrium and ovary.
The IARC (2007) review also concluded that there is sufficient
evidence in humans for the carcinogenicity of combined oestro-
gen–progestogen menopausal therapy in the breast. With respect
to endometrial cancer, combined oestrogen–progestogen meno-
pausal therapy was evaluated as carcinogenic when progestogens
are taken for o10 days per month, while there was evidence
suggesting lack of carcinogenicity in the endometrium when
progestogens are taken daily. The risk for endometrial cancer is
inversely associated with the number of days per month that
progestogens are added to the regimen.
The use of hormonal preparations in the UK has declined
dramatically in recent years. According to the data from
prescription cost analysis (PCA) on the annual numbers of
prescriptions for oestrogens and progestogens dispensed in the
community, there has been a marked decline in prescriptions for
hormonal preparations in England since 2000–1 (http://www.ic.
nhs.uk/statistics-and-data-collections/primary-care/prescriptions/
prescription-cost-analysis-england–2009).
In this section, the population-attributable fraction (PAF) of
cancers diagnosed in women in the UK in 2010 due to current or
past use of hormonal preparations is estimated.
METHODS
Prevalence of exposure to hormonal preparations
To examine the changes in use of prescribed agents by age group,
data were obtained from the general practice research database
(GPRD). The GPRD is the world’s largest computerised database of
anonymised longitudinal medical records from primary care.
Currently data are collected on over 3.4 million active patients
from around 450 primary-care practices throughout the UK. Data
were abstracted for women, aged 15 to 485 (in 5-year age bands),
annually from 1992 to 2009. A list of female sex hormone products
were identified and classed into one of the following British
National Formulary (BNF) categories:
6.4.1.0 – Oestrogen only hormone replacement therapy (HRT)
6.4.1.1 – Combined oestrogen/progesterone HRT
6.4.1.2 – Progestogens
6.4.1.3 – Tibolone
6.4.1.4 – Raloxifene
7.3.1 – Combined hormonal contraceptives
7.3.2.1 – Oral progestogen-only contraceptives
7.3.2.2 – Parenteral progestogen-only contraceptives
7.3.2.3 – Intra-uterine progestogen-only device
Other – Other female sex hormones.
The information was provided by GPRD as prevalence of women
with a prescription per 1000 patients registered at calendar year
mid-point, stratified by calendar year, age band and BNF code. As
well as prevalence of current (2009) use, the prevalence of ex-users
in the same year was estimated, with the simplifying assumption
that users do not stop and restart the same preparation. Thus, the
prevalence of ex-users of o1 year (Pex(1)) is given by
Pexð1Þi;a ¼½ Pcurrenti 1;a 1  ½ Pcurrenti;a 
where i is the year and a age.
In addition, it was assumed that prescription of progesterone-
only preparations in post-menopausal women was accompanied
by oestrogens (with each hormone dispensed separately, rather
than as a combined preparation), so that prevalence of use of
unopposed oestrogens (P(oes)) is given by the difference
(P(oes) P(prog)).
Risks of oral contraceptive (OC) use
Breast cancer The Collaborative Group on Hormonal Factors in
Breast Cancer (1996) brought together and reanalysed the world-
wide epidemiological evidence on the relation between breast
cancer risk and use of hormonal contraceptives. Table 1 shows the
excess relative risks (ERRs) (¼relative risk (RR) 1) associated
with current and past use of combined (oestrogen plus progester-
one) OC preparations. Duration of use, age at first use, and the
dose and type of hormone within the contraceptives had little
additional effect on breast cancer risk, once recency of use had
been taken into account. Hormonal contraceptives containing only
progestogens comprised o3% of the study population, but results *Correspondence: Professor DM Parkin; E-mail: d.m.parkin@qmul.ac.uk
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in risk for use in the previous 5 years: ERR 0.17; but no evidence of
an increase in risk 10 or more years after stopping use); risks are
assumed to be the same as for combined contraceptive prepara-
tions (Table 1).
Cancer of the cervix uteri Smith et al (2003) combined the results
from studies published between 1966 and 2002 to examine the
relationship between the risk of cancers of the cervix and duration
and recency of use of hormonal contraceptives, taking into account
potential confounding factors, such as HPV status, sexual partners,
screening history, smoking and use of barrier contraceptives. More
recently, the International Collaboration of Epidemiological
Studies of Cervical Cancer (2007) obtained the original data from
24 studies to conduct a pooled analysis. They found that risk of
cervical cancer increased by a factor of 1.07 for each year of use of
hormonal contraception (or 1.38 (1.30–1.46) for 5 years use). In
ex-users, the excess risk is approximately halved 2–4 years after
cessation, and halved again after 5–9 years. There was no
significant excess risk 10 years after cessation of use.
Duration of use of contraception, among current users, by age
group, is not available from any UK source. In the multicentre
study of the International Collaboration (2007), the mean duration
of use, in control women, was 6 years. Clearly, the controls for
cases of cervix cancer are older women, with a mean age of about
40. Younger women would have had shorter durations of use: we
assume 2 years at ages 15–19 and 4 years at ages 20–24, so that the
ERRs of current users are as shown in Table 2. For ex-users, we
assume a halving of risk after 2–4 years, and halving again at 5–9,
as in the International Collaboration Study (2007).
Cancer of the corpus uteri (endometrium) IARC (2007) concluded
that there is convincing evidence in humans for a protective effect
of combined oral oestrogen–progestogen contraceptives against
carcinogenicity in the endometrium. They reviewed four cohort
studies and 21 case–control studies reported up to 2003, which
consistently showed that the risk for endometrial cancer in women
who had taken these medications is approximately halved. The
reduction in risk was generally greater with longer duration of use
of combined hormonal contraceptives and persisted for at least 15
years after cessation of use. More recently, the EPIC study (Dossus
et al, 2010) found that women who had ever used OCs had a risk of
0.63 compared with never users, and this was just 0.44 in women
who had used OCs for X10 years.
Schlesselman (1997) conducted a meta-analysis of studies
reported up to 1993, and estimated the risk of combined OC use
in relation to duration of use, and time since last used. The
estimate of RR by duration of use was given by
RRdur ¼ exp½ 0:023   0:493 lnðyears þ 1Þ 
This is equivalent to a risk of 0.44 for 4 years use, 0.33 for 8 years
use and 0.28 for 12 years use.
The estimate of RR by years since last use of combined OCs
(recency of use) was given by
RRrec ¼ exp½ 1:721 þ 0:346 lnðyears þ 1Þ 
This is equivalent to a risk of 0.33 for use within the last 10 years,
0.41 for use within the last 10 years and 0.51 for use within the last
20 years.
Ovarian cancer The IARC (2007) review concluded that women
who had ever used combined hormonal contraceptives orally
had an overall reduced risk for ovarian cancer, and an inverse
relationship was observed with duration of use. The reduced risk
appeared to persist for at least 20 years after cessation of use. In
the combined analysis by the Collaborative Group on Epidemio-
logical Studies of Ovarian Cancer (Collaborative Group, 2008), the
overall reduction in ovarian cancer risk in ever vs never users
was 27%. Table 3 shows the RRs by duration of use and time since
last use.
The effect of combined hormonal contraceptive use on the
reduction of risk for ovarian cancer is not confined to any
particular type of oral formulation nor to any histological type of
ovarian cancer, although it was less consistent for mucinous than
for other types in several studies.
Liver cancer Although the IARC (2007) review concluded that
combined oral oestrogen–progestogen contraceptives are carcino-
genic for the liver, the conclusion was based on a selected group of
case–control studies (in populations with ‘low prevalence of
hepatitis B viral infection and chronic liver disease’), with no
cohort studies providing a conclusive result. A more recent meta-
analysis of case–control studies (Maheshwari et al, 2007) did not
obtain a conclusive result based on 12 case–control studies
(pooled estimate of ORs 1.57 (95% CI¼0.96–2.54, P¼0.07)), or
eight studies reporting adjusted ORs (in addition to age and sex) –
the pooled estimate was 1.45 (95% CI¼0.93–2.27, P¼0.11).
In any case, liver cancer is rare in UK, and there were only some
190 cases below age 50 in UK in 2005; therefore, the number of
cases possibly attributable to OC use is trivial.
Table 2 Excess relative risks for cervical cancer in relation to use of OCs,
by age
Time since cessation of
Excess relative risk by age group
OCs (years) 15–19 20–24 25+
Current use 0.14 0.30 0.48
o1 0.14 0.30 0.48
2–4 0.07 0.15 0.24
5–9 — 0.07 0.12
X10 — — 0
Abbreviation: OC¼oral contraceptive.
Table 1 Excess relative risk of breast cancer associated with current and
past use of combined OC preparations
Time since cessation of OCs
(years)
Excess relative risk of breast
cancer
Current use 0.24
1–4 0.16
5–9 0.07
X10 0
Abbreviation: OC¼oral contraceptive.
Table 3 Risk of ovarian cancer in relation to duration of use, and time
since last use of OCs (Collaborative Group, 2008)
Risk of ovarian cancer by
duration of use of OCs
Time since use of OCs (years) o5years 5–9years 410 years
o10 0.88 0.52 0.39
10–19 0.85 0.62 0.51
29–29 0.81 0.69 0.60
X30 0.83 — —
Abbreviations: OC¼oral contraceptive.
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Breast cancer The magnitude of the risk of postmenopausal
hormone therapy for the risk of breast cancer has been quantified
based on studies in the USA, Europe and the UK (Collaborative
Group, 1997; Writing Group, 2002; Chlebowski et al, 2003; Beral,
2003; Bakken et al, 2011). In the Million Women Study (Beral,
2003) for example, the RR of breast cancer in current users of HRT
was 1.66 (95% CI 1.58–1.75, Po0.0001). Incidence was signifi-
cantly increased for current users of preparations containing
oestrogen only (1.30), progestogen only (2.02), oestrogen–
progestogen (2.00) and tibolone (1.45). Results varied little
between specific oestrogens and progestogens or their doses, or
between continuous and sequential regimens. Past users of HRT
were, however, not at an increased risk of disease (1.01 (0.94–
1.09)). In past users, the risk of breast cancer did not differ
significantly from that of never users of HRT, for use that ceased at
o5 years, 5–9 years and X10 years previously, although among
women who ceased use of HRT in the previous year, the RR of
breast cancer was slightly increased (1.14 (1.01–1.28)). The ERRs
are shown in Table 4.
Cancer of the corpus uteri (endometrium) The Million Women
Study (Beral et al, 2005) found that hormone-replacement therapy
containing oestrogen alone increased the risk of endometrial
cancer. The RR of endometrial cancer in current users of
oestrogen-only HRT was 1.80 (1.19–2.70), while there was no
increase in risk in past users (RR 0.97 (0.50–1.87)).
The risk of endometrial cancer was also increased by tibolone.
The RR in current users of tibolone was 2.02 (1.58–2.59), while it
was 1.23 (0.76–1.99) in past users. Past users had ceased use an
average of 2.7 years previously, so that the excess risk in past users
of tibolone (0.23) was assumed to last for up to 4 years.
Progestogens, however, counteract the adverse effect of oestro-
gens on the endometrium, and the effect of continuous combined
preparations was a reduction in risk (RR¼0.71), while there was
no significant risk (or protection) from use of cyclic preparations
(RR¼1.05, 95% CI 0.91–1.22). As the data from GPRD did not
distinguish between the proportion of combined oestrogen–
progestogen preparations that had been prescribed as continuous
combined preparations, or cyclic combined preparations, it was
assumed that these were in the ratio of 1:2, as in the Million
Women study. An RR for all such preparations was obtained by
weighting the RRs of current use (0.75 for continuous, 1.05 for
cyclic) accordingly, yielding an RR of 0.95 and an ERR of  0.05
(Table 6). There were no significant differences in risk between
current and past users of combined preparations (average time
since cessation for women who had taken cyclic preparations was
2.7 years, and that for continuous 1.2 years).
The ERRs used to estimate PAF are shown in Table 5.
Ovarian cancer The IARC (2007) review concluded that the
studies available were inadequate to evaluate an association
between ovarian cancer and combined oestrogen–progestogen
hormonal therapy. However, more data are now available. In a
meta-analysis of eight cohort and 19 case–control studies by Zhou
et al (2008), ever use of HRT was associated with a 19–24%
increase in risk of ovarian cancer, with a greater risk of oestrogen-
only therapy compared to oestrogen–progestogen therapy. A more
recent meta-analysis of 14 population-based studies found a risk of
1.22 associated with 5 years of use of oestrogen therapy, while in
users of combined therapy it was 1.1 (Pearce et al, 2009). In the
Cancer Prevention II Nutrition Cohort in the USA (Hildebrand
et al, 2010), current oestrogen use was associated with a risk of
1.70 (for use of p10 years), while there was no increased risk for
users of combined preparations, or in former users of either.
After an average 5.3 years of follow-up in the Million Women
Study (Million Women Study Collaborators, 2007), the risk in
current users of HRT was 1.20, greater for oestrogen-only (1.34)
than for combined (1.14) or other preparations (1.22). The risk in
past users was not increased. These values were used to estimate
PAF in the UK in 2010.
Attributable fractions
Breast cancer We use the prevalence of current and past use of
OC agents, and post-menopausal therapy in 2009 to calculate the
excess risk in current users, given the ERRs in Tables 1 and 4. It
was assumed that prescription of progestogen-only preparations in
post-menopausal women was probably accompanied by oestro-
gens (with each hormone dispensed separately, rather than as a
combined preparation). Total excess risk due to hormonal
preparations is obtained by summing the excess risks for current
and past users of HRT and OCs.
Cervix cancer With the ERRs in Table 2 and prevalence of
current and past use of OCs, total excess risk due to OCs is
obtained by summing the excess risks for current and past users
(as for breast cancer, above).
Endometrial cancer The protective effect of combined OCs
against endometrial cancer is related to duration of use, and, in
ex-users, time since last use, as described above. The prevalence of
current and past use of OCs in the UK (by age, time since used and
duration of use) is not documented. We used data from the Million
Women Study (age groups 50–64) (Million Women Study
Collaborative Group, 1999), from a study of post-menopausal
women in Norfolk (Chan et al, 2008), and from a case–control
study of pre-menopausal women (aged 36–44) by Roddam et al
(2007) to estimate the proportions of current and past users of
OCs. Prevalence of current and recent (o10 years) ex-users at ages
15–34 was estimated from the GPRD data as described above.
With these data, and the equations proposed by Schlesselman
(1997), estimates of RR by age, duration of use and time since last
use could be made for 2009. These were applied to the estimated
Table 4 Excess relative risks of breast cancer in current and past users
of HRT
Excess relative risk of breast cancer
Preparation
Current HRT
users
Past HRT users
(o1 year)
Oestrogen only 0.3 0.06
Oestrogen+progestogen combinations 1 0.21
Progestogens 1.02 0.22
Tibolone 0.45 0.10
Raloxifene hydrochloride 0 0.00
All 0.66 0.14
Abbreviation: HRT¼hormone replacement therapy (postmenopausal hormones).
Table 5 Excess relative risks of endometrial cancer in current and past
users of HRT
Excess relative risks of endometrial cancer
Preparation
Current
HRT users
Past HRT users (used HRT
within the past 4 years)
Oestrogen only 0.8 0.00
Oestrogens+progestogen
combinations
 0.05  0.05
Tibolone 1.02 0.23
Abbreviation: HRT¼hormone replacement therapy.
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prevented by current and past use of combined OCs.
For post-menopausal hormone therapy, the prevalence of use at
ages X45 in 2009 was used to calculate the excess risk of
endometrial cancer in current users of oestrogen-only prepara-
tions, and of tibolone, with an ERR for oestrogen of 0.80 and for
tibolone of 1.02 (Table 5). As noted earlier, it was assumed that
progestogen-only preparations in post-menopausal women were
accompanied by oestrogens (with each hormone dispensed
separately, rather than as a combined preparation), so that
prevalence of use of oestrogen alone is represented by the
difference (oestrogen progestogen).
Ovarian cancer The prevalence of current and past use of OCs in
the UK (by age, time since used and duration of use) was estimated
as described for endometrial cancer. With the relevant protective
effects from the Collaborative Group study (2008) shown in
Table 3, the proportion of cancers being prevented by current and
past use of OCs in 2010 can be estimated.
For use of post-menopausal hormone therapy, we used the
prevalence of use of post-menopausal therapy (ages 45 and over)
in 2009 to calculate the excess risk of ovarian cancer in current
users of the different preparations, assuming the RRs from the
Million Women Study (Million Women Study Collaborators,
2007): oestrogen-only HRT: 1.34, combined preparations: 1.14,
others: 1.22 (as usual, also assuming that prescription of
progestogen-only preparations in postmenopausal women was
accompanied by oestrogens).
RESULTS
Prevalence of exposure to hormonal preparations
Prevalence of use of female sex hormones is greatest in the age
group 20–24, when almost 60% of women were receiving a
prescription for such agents (Figure 1).
Prescribed hormones in the UK were predominantly combined
oestrogen–progesterone OCs, with a smaller proportion of
progestogen-only contraceptives, increasing over time. Prevalence
of use of contraceptive agents declines with age. The estimated age-
specific prevalence, based on prescription data, is very similar to
that from the ‘Omnibus survey’ of 2006–7 (Lader, 2007), reporting
prevalence of use of OCs in England as 64% at ages 20–24 and 28%
at 35–39. Use of hormonal (non-contraceptive) agents exceeds use
of contraceptive agents by age 45–49, and increases to a maximum
prevalence in the age group 50–54.
There have been marked changes in use over time. Use of
hormonal preparations increased for several years from 1992 to
reach a maximum in around 2000, and then declined. The year of
maximum use (in terms of women receiving prescriptions) varies
with age, from 1997 (ages 45–49), to 2001 (55–59) and 2002 (65–
69). Figure 2 shows the prevalence of use of different hormonal
agents in women aged 45–69. The changes concern in particular
combined oestrogen–progesterone preparations, but use of
oestrogen-only agents has also declined.
Attributable fractions
Table 6 summarises the estimates of PAF due to use of OCs and
post-menopausal hormone therapy, and the net result of both, on
the estimated numbers of cases of breast, cervical, endometrial and
ovarian cancers in 2010.
Breast cancer Both post-menopausal hormone therapy and OCs
increase the risk of breast cancer. Post-menopausal hormones are
estimated to be responsible for 3.2% of breast cancers in 2010, and
OCs for 1.1%, so that both sources of hormones together are
responsible for 4.3% of breast cancers. Figure 3 shows the
estimated fractions that are attributable to hormones, by age
group. The excess risk of breast cancer was highest (a 14% excess)
in the age ranges with maximum use of contraceptives (20–24) so
that the fraction of breast cancer cases attributable to hormones
was about 12%.
Cervix cancer The fraction of cervix cancer cases attributable to
OCs is 9.7%, with much larger proportions (up to 22%) in younger
women (Figure 4).
Endometrial cancer It is estimated that current and past use of
OCs is preventing almost 17% of cases of endometrial cancers that
would otherwise have occurred.
Because the bulk of post-menopausal hormones are prescribed
as combined oestrogen–progestogen preparations, with a small
net protective effect (assuming that two-thirds of them are given as
continuous combined preparations), the net effect on the risk of
endometrial cancer is small. The estimate of the fraction of
endometrial cancers attributable to use of post-menopausal
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being in age group 55–59.
Figure 5 illustrates the net effects of OCs and post-menopausal
hormones (HRT) by age group.
Ovarian cancer Although there is a small increase in risk of
ovarian cancer in post-menopausal women using hormonal
preparations (the PAF is 0.7%), this effect is overwhelmed by the
longstanding protection provided by current and past use of OCs,
which are estimated to be preventing 9.3% of the ovarian cancers
that would otherwise have occurred (Table 6).
Figure 6 illustrates the net effects of OCs and post-menopausal
hormones (HRT) by age group. Overall in 2010, there would be
some 655 fewer cases of ovarian cancer than would have been the
Table 6 Estimated cases of cancers of the breast, cervix, endometrium and ovary occurring in 2010 attributable to exposure to hormones
Cases attributable to exposure to hormones, by hormone type
HRT Oral contraceptives Both
Cancer and age (years)
Observed
cases
Excess attributable
cases PAF (%)
Excess attributable
cases PAF (%)
Excess attributable
cases PAF (%)
Breast
o40 2018 0 0.0 192 9.5 192 9.5
40–49 6829 376 5.5 343 5.0 719 10.5
50–64 16851 921 5.5 0 0.0 921 5.5
X65 22687 235 1.0 0 0.0 235 1.0
All ages 48385 1531 3.2 535 1.1 2067 4.3
Cervix
o40 1108 0 0.0 203 18.3 203 18.3
40–49 544 0 0.0 54 10.0 54 10.0
50–64 494 0 0.0 4 0.8 0 0.0
X65 547 0 0.0 0 0.0 0 0.0
All ages 2691 0 0.0 261 9.7 261 9.7
Corpus uteri (endometrium)
o40 104 0 0.0  74  41.4  74  41.4
40–49 454 0 0.1  283  38.4  283  38.4
50–64 3035 58 1.9  832  21.5  774  20.3
X65 4602 37 0.8  479  9.4  441  8.7
All ages 8195 95 1.2  1667  16.9  1571  16.1
Ovary
o40 445 0 0.0  94  17.4  94  17.4
40–49 706 7 1.0  172  19.6  165  18.9
50–64 2004 28 1.4  282  12.3  254  11.2
X65 3665 13 0.4  156  4.1  143  3.8
All ages 6820 48 0.7  703  9.3  655  8.8
Abbreviations: HRT¼hormone replacement therapy (postmenopausal hormones); PAF¼population-attributable fraction.
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post-menopausal hormonal therapy).
Summary
Table 7 summarises the results. Overall, a net total of 1675 cancers
occurring in 2010 in the UK can be attributed to current or past
use of post-menopausal hormonal preparations by women,
representing 1.1% of all cancers in women (0.5% for both sexes).
However, the net effect of the use of OCs is protective – with almost
1600 fewer cancers than would have been the case if they had not
been used.
The net effect of hormone use is therefore very tiny – just 102
cases attributable to their use.
DISCUSSION
In this paper, we used the RR of cancer in relation to use of post-
menopausal hormones from the Million Women Study (Beral, 2003;
Beral et al, 2005, Million Women Study Collaborators, 2007) to
estimate the likely impact of hormone use on the number of cancer
cases at ages 445 in the UK in 2010. This study recorded the use of
HRT in women aged 50–64 at the time of enrolment, and followed
them for an average of 2.6 years for breast cancer incidence, 3.4
years for incidence of endometrial cancers and 5.3 years for ovarian
cancers. For breast cancer, the risk among women who were current
users of HRT was 1.66, a result not very different from that observed
in the Women’s Health Initiative randomised trial for women aged
50–79, in whom the risk of breast cancer in women taking
oestrogen plus progesterone was 1.49 after an average 5.6 years of
follow-up; the excess relative to the placebo group emerged after 3
years, and continued to widen until the maximum follow-up period
of 7 years (Chlebowski et al, 2003). The RRs in the EPIC study
(Bakken et al, 2011) after a mean follow-up of 8.6 years were 1.42 for
current users of oestrogen-only and 1.77 for current users of
combined preparations. For ovarian cancer, the risks observed in
the Million Women Study were very similar to those in the meta-
analyses of Zhou et al (2008) and Pearce et al (2009). With respect to
endometrial cancer, however, the EPIC study (Allen et al,2 0 1 0 )
found rather higher risks for current users of hormone therapy after
9 years of follow-up than the Million Women Study (2.52 for
oestrogen-only HT, 2.96 for tibolone and 1.41 for combined
oestrogen–progestogen (although risks differed according to regi-
men and type of progestogen constituent).
As an increased risk of breast and endometrial cancer is observed
in past users of at least some hormonal preparations by post-
menopausal women, it is important to take this into account,
especially as the prevalence of current use has been falling
dramatically in the UK since around 2000–1 (Figure 2, Watson
et al, 2007). In fact, we have no information on prevalence of ex-
users in the population, and can only estimate it in terms of the
difference in population prevalence from one year to the next, which
is surely an underestimate. On the other hand, prevalence of use of
hormonal preparations is calculated by dividing the number of
women who receive prescriptions for hormonal preparations by the
number at risk (in the General Practice Research Database), and this
prevalence is assumed to apply to the UK population. In fact, it is
possible that many women who receive hormonal preparations have
had a hysterectomy, and so would not be at risk of endometrial
cancer, so that the attributable fractions for this cancer are
overestimated.
Current and recent use of OCs increase the risk of breast and
cervical cancer, and decrease the risk of endometrial and
ovarian cancer, the latter effects lasting 20 years or more.
Although the data on current use of oral contraception should
be accurate, information on past use is much less certain, and
estimates were based on published data from recent UK studies.
T h ep r o t e c t i v ee f f e c to fO C si sc o n s i d e r a b l yg r e a t e rw i t hr e s p e c t
to endometrial cancer, as might be expected from the markedly
reduced risks in current and past users (IARC, 2007). Pike’s
(1987) model of the effect of hormones on cancers of the female
reproductive organs estimates that 5-year use of oral contra-
ception delays the rise in age-specific incidence of endometrial
cancer by 5 years, thus producing lower rates at older ages. On
this basis, Key and Pike (1988) predicted that 5-year use of
combined OCs beginning at age 28 would produce a 60%
reduction in lifetime risk.
It seems that OCs are beneficial not only in preventing unwanted
pregnancy but also, on balance, in reducing the numbers of
cancers that would otherwise have occurred. For this reason, in the
final summary section (Section 16) we include only post-
menopausal hormone therapy as a risk factor contributing to
cancers in the UK.
See acknowledgements on page Si.
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Figure 6 Ovarian cancer: observed cases, including the number caused
by HRT and those estimated to be prevented by current and past use of
oral contraceptives (OCs), UK, 2010.
Table 7 Estimated cases of cancer occurring in women in 2010, and the fraction attributable to hormone exposures
All cancer cases by type of hormone exposure
a
HRT Oral contraceptives Both
Age (years)
Observed
cases
Excess attributable
cases PAF (%)
Excess attributable
cases PAF (%)
Excess attributable
cases PAF (%)
o40 8140 0 0.0 228 2.8 228 2.8
40–49 13667 384 2.8  58  0.4 326 2.4
50–64 41338 1006 2.4  1109  2.6  103  0.2
X65 92439 285 0.3  634  0.7  349  0.4
All ages 155584 1675 1.1  1573  1.0 102 0.1
Abbreviations: HRT¼hormone replacement therapy (postmenopausal hormones); PAF¼population-attributable fraction.
aExcluding non-melanoma skin cancer.
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